HomeCompareSESN vs PLD

SESN vs PLD: Dividend Comparison 2026

SESN yields 318.07% · PLD yields 3.10%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SESN wins by $2245.91M in total portfolio value
10 years
SESN
SESN
● Live price
318.07%
Share price
$0.63
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2251.82M
Annual income
$1,391,325,451.55
Full SESN calculator →
PLD
PLD
● Live price
3.10%
Share price
$132.18
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$5.91M
Annual income
$4,750,725.19
Full PLD calculator →

Portfolio growth — SESN vs PLD

📍 SESN pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSESNPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SESN + PLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SESN pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SESN
Annual income on $10K today (after 15% tax)
$27,035.62/yr
After 10yr DRIP, annual income (after tax)
$1,182,626,633.82/yr
PLD
Annual income on $10K today (after 15% tax)
$263.66/yr
After 10yr DRIP, annual income (after tax)
$4,038,116.41/yr
At 15% tax rate, SESN beats the other by $1,178,588,517.41/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SESN + PLD for your $10,000?

SESN: 50%PLD: 50%
100% PLD50/50100% SESN
Portfolio after 10yr
$1128.87M
Annual income
$698,038,088.37/yr
Blended yield
61.84%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

SESN
Analyst Ratings
5
Buy
3
Hold
Consensus: Buy
Altman Z
-26.2
Piotroski
3/9
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+2.9% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SESN buys
0
PLD buys
0
No recent congressional trades found for SESN or PLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSESNPLD
Forward yield318.07%3.10%
Annual dividend / share$2.00$4.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%74.4%
Portfolio after 10y$2251.82M$5.91M
Annual income after 10y$1,391,325,451.55$4,750,725.19
Total dividends collected$2167.12M$5.78M
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyBuy

Year-by-year: SESN vs PLD ($10,000, DRIP)

YearSESN PortfolioSESN Income/yrPLD PortfolioPLD Income/yrGap
1← crossover$42,507$31,806.62$11,241$540.96+$31.3KSESN
2$171,836$126,354.35$13,019$991.13+$158.8KSESN
3$661,246$477,381.03$15,801$1,870.97+$645.4KSESN
4$2,424,371$1,716,837.53$20,609$3,701.21+$2.40MSESN
5$8,476,840$5,882,763.50$29,919$7,867.97+$8.45MSESN
6$28,293,724$19,223,504.84$50,631$18,617.74+$28.24MSESN
7$90,240,261$59,965,976.10$105,528$51,352.20+$90.13MSESN
8$275,301,033$178,743,953.65$287,364$174,449.42+$275.01MSESN
9$804,202,218$509,630,112.70$1,081,760$774,280.77+$803.12MSESN
10$2,251,821,824$1,391,325,451.55$5,908,209$4,750,725.19+$2245.91MSESN

SESN vs PLD: Complete Analysis 2026

SESNStock

Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer. Its lead product candidates include Vicineum, a locally-administered targeted fusion protein that is in Phase III clinical trials for the treatment of bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer; to treat non-muscle invasive carcinoma in situ of the bladder in patients previously treated with BCG; and for the treatment of squamous cell carcinoma of the head and neck, as well as VB6-845d, a product candidate for use in the treatment of various types of an anti-epithelial cell adhesion molecule-positive solid tumors. Sesen Bio, Inc. has an agreement with Leiden University Medical Center to co-develop an imaging agent. The company was formerly known as Eleven Biotherapeutics, Inc. and changed its name to Sesen Bio, Inc. in May 2018. Sesen Bio, Inc. was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Full SESN Calculator →

PLDREIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this SESN vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SESN vs SCHDSESN vs JEPISESN vs OSESN vs KOSESN vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.